SAFETY AND TOLERANCE OF VPA-985 FOR PATIENTS WITH CONGESTIVE HEART FAILURE

VPA-985 对充血性心力衰竭患者的安全性和耐受性

• 批准号: 6245271
• 负责人: WILLIAM T ABRAHAM
• 金额: $ 2.65万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-14 至 1997-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6245271
• 关键词: cardiovascular disorder chemotherapy; clinical research; clinical trials; congestive heart failure; drug screening /evaluation; drug tolerance; human subject; human therapy evaluation; kidney function; neurohormones; oral administration; vasopressins

This is an investigator-initiated evaluation of the renal and neurohormonal effects of the first oral nonpeptide V2 receptor vasopressin antagonist available for clinical research in the united states. The study, set up as a collaborative effort with the gcrc at the university of iowa investigates the role of vasopressin in the renal water retention of heart failure. Preliminary data are encouraging and will be presented at the American College of Cardiology 46th Annual Scientific Session in March 1997.

这是一项由研究者发起的肾脏和